E-LIB Suche - Ergebnisse für: Helen X. Chen

1

Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blo..:

Patel, Sandip P ; Othus, Megan ; Chae, Young Kwang...
Journal for ImmunoTherapy of Cancer. 12 (2024) 7 - p. e009074 , 2024

Link: https://doi.org/10.1136/..

2

The New NCI Precision Medicine Trials:

Harris, Lyndsay N. ; Blanke, Charles D. ; Erba, Harry P....
Clinical Cancer Research. 29 (2023) 23 - p. 4728-4732 , 2023

Link: https://doi.org/10.1158/..

3

Society for Immunotherapy of Cancer (SITC) consensus defini..:

Rizvi, Naiyer ; Ademuyiwa, Foluso O ; Cao, Z Alexander...
Journal for ImmunoTherapy of Cancer. 11 (2023) 3 - p. e005920 , 2023

Link: https://doi.org/10.1136/..

4

Mechanisms of response and resistance to combined decitabin..:

Penter, Livius ; Liu, Yang ; Wolff, Jacquelyn O....
Blood. 141 (2023) 15 - p. 1817-1830 , 2023

Link: https://doi.org/10.1182/..

5

Dose‐escalation trial of combination dabrafenib, trametinib..:

Mooradian, Meghan J. ; Cleary, James M. ; Giobbie‐Hurder, Anita...
Cancer. 129 (2023) 12 - p. 1904-1918 , 2023

Link: https://doi.org/10.1002/..

6

Phase I pharmacokinetic study of single agent trametinib in..:

Voon, Pei Jye ; Chen, Eric X. ; Chen, Helen X....
Journal of Experimental & Clinical Cancer Research. 41 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

7

Ocular adverse events in PD-1 and PD-L1 inhibitors:

Young, LeAnne ; Finnigan, Shanda ; Streicher, Howard...
Journal for ImmunoTherapy of Cancer. 9 (2021) 7 - p. e002119 , 2021

Link: https://doi.org/10.1136/..

8

A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 B..:

Patel, Sandip Pravin ; Mayerson, Edward ; Chae, Young Kwang...
Cancer. 127 (2021) 17 - p. 3194-3201 , 2021

Link: https://doi.org/10.1002/..

9

Defining tumor resistance to PD-1 pathway blockade: recomme..:

Kluger, Harriet M. ; Tawbi, Hussein A. ; Ascierto, Maria L....
Journal for ImmunoTherapy of Cancer. 8 (2020) 1 - p. e000398 , 2020

Link: https://doi.org/10.1136/..

10

The moderation effect of social factors on marketing factor..:

Wu, Xiaochuang ; Chen, Helen X. ; Li, Xiaohong
Transnational Corporations Review. 11 (2019) 2 - p. 157-165 , 2019

Link: https://doi.org/10.1080/..

11

Vismodegib or cixutumumab in combination with standard chem..:

Belani, Chandra P. ; Dahlberg, Suzanne E. ; Rudin, Charles M....
Cancer. 122 (2016) 15 - p. 2371-2378 , 2016

Link: https://doi.org/10.1002/..

12

The Prevalence and Impact of Hyperglycemia and Hyperlipidem..:

Busaidy, Naifa L. ; LoRusso, Patricia ; Lawhorn, Kristie...
The Oncologist. 20 (2015) 7 - p. 737-741 , 2015

Link: https://doi.org/10.1634/..

13

A phase II study of cixutumumab (IMC-A12, NSC742460) in adv..:

Abou-Alfa, Ghassan K. ; Capanu, Marinela ; O'Reilly, Eileen M....
Journal of Hepatology. 60 (2014) 2 - p. 319-324 , 2014

Link: https://doi.org/10.1016/..

14

A phase II trial of bevacizumab plus temsirolimus in patien..:

Knox, Jennifer J. ; Qin, Rui ; Strosberg, Jonathan R....
Investigational New Drugs. 33 (2014) 1 - p. 241-246 , 2014

Link: https://doi.org/10.1007/..

15

Incidence of Mucositis in Patients Treated With Temsirolimu..:

Liu, Xiaochun ; LoRusso, Patricia ; Mita, Monica...
The Oncologist. 19 (2014) 4 - p. 426-428 , 2014

Link: https://doi.org/10.1634/..